At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Trial of IMC-A12 in Combination With Temsirolimus in Patients With Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Cixutumumab, Laboratory Biomarker Analysis, and 2 other interventions for Male Breast Carcinoma and 2 related conditions. Completed, enrolled 48 participants across 192 sites.
Detailed Summary
This phase I/II trial is studying the side effects and best dose of cixutumumab when given together with temsirolimus and to see how well they work in treating patients with breast cancer that has recurred (come back) at or near the same place as the original (primary) tumor or has spread to other places in the body. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways by targeting certain cells. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving cixutumumab together with temsirolimus may be a better treatment for breast cancer.
Study Details
Timeline
Interventions
Given IV
Correlative studies
Correlative studies
Given IV